In the following Review by Margaret O James & Peter W Stacpoole, ‘Pharmacogenetic considerations with dichloroacetate dosing James & Stacpoole, “Pharmacogenetic considerations with dichloroacetate dosing’, which appeared in the May 2016 issue of Pharmacogenomics 17(7), 743–753 (2016), the ‘Financial & competing interests disclosure’ on page 751 was published incorrectly.
The correct ‘Financial & competing interest disclosure’ should read as:
“The authors’ work discussed in this manuscript was funded in part by the US Public Health Service 1RO1 GM 099871, in part by the Brain and Tissue Bank for Developmental Disorders, University of Maryland, Baltimore and University of Miami (NO1 HD90011) and in part by the NIH/NCATS Clinical and Translational Science award to the University of Florida UL1 TR000064. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.”
The authors and editors of Pharmacogenomics would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.